|
rdf:type |
|
|
lifeskim:mentions |
umls-concept:C0003873,
umls-concept:C0005522,
umls-concept:C0008976,
umls-concept:C0027540,
umls-concept:C0030705,
umls-concept:C0063717,
umls-concept:C0085415,
umls-concept:C0205269,
umls-concept:C0332161,
umls-concept:C1274040,
umls-concept:C1514761,
umls-concept:C1521761,
umls-concept:C1609165
|
|
pubmed:issue |
11
|
|
pubmed:dateCreated |
2008-10-15
|
|
pubmed:databankReference |
|
|
pubmed:abstractText |
The phase III RADIATE study examined the efficacy and safety of tocilizumab, an anti-IL-6 receptor monoclonal antibody in patients with rheumatoid arthritis (RA) refractory to tumour necrosis factor (TNF) antagonist therapy.
|
|
pubmed:commentsCorrections |
|
|
pubmed:language |
eng
|
|
pubmed:journal |
|
|
pubmed:citationSubset |
IM
|
|
pubmed:chemical |
http://linkedlifedata.com/resource/pubmed/chemical/Antibodies, Monoclonal,
http://linkedlifedata.com/resource/pubmed/chemical/Antibodies, Monoclonal, Humanized,
http://linkedlifedata.com/resource/pubmed/chemical/Antirheumatic Agents,
http://linkedlifedata.com/resource/pubmed/chemical/Methotrexate,
http://linkedlifedata.com/resource/pubmed/chemical/Receptors, Interleukin-6,
http://linkedlifedata.com/resource/pubmed/chemical/Tumor Necrosis Factor-alpha,
http://linkedlifedata.com/resource/pubmed/chemical/tocilizumab
|
|
pubmed:status |
MEDLINE
|
|
pubmed:month |
Nov
|
|
pubmed:issn |
1468-2060
|
|
pubmed:author |
|
|
pubmed:issnType |
Electronic
|
|
pubmed:volume |
67
|
|
pubmed:owner |
NLM
|
|
pubmed:authorsComplete |
Y
|
|
pubmed:pagination |
1516-23
|
|
pubmed:dateRevised |
2011-11-17
|
|
pubmed:meshHeading |
pubmed-meshheading:18625622-Adolescent,
pubmed-meshheading:18625622-Adult,
pubmed-meshheading:18625622-Aged,
pubmed-meshheading:18625622-Antibodies, Monoclonal,
pubmed-meshheading:18625622-Antibodies, Monoclonal, Humanized,
pubmed-meshheading:18625622-Antirheumatic Agents,
pubmed-meshheading:18625622-Arthritis, Rheumatoid,
pubmed-meshheading:18625622-Dose-Response Relationship, Drug,
pubmed-meshheading:18625622-Double-Blind Method,
pubmed-meshheading:18625622-Drug Therapy, Combination,
pubmed-meshheading:18625622-Female,
pubmed-meshheading:18625622-Humans,
pubmed-meshheading:18625622-Male,
pubmed-meshheading:18625622-Methotrexate,
pubmed-meshheading:18625622-Middle Aged,
pubmed-meshheading:18625622-Receptors, Interleukin-6,
pubmed-meshheading:18625622-Severity of Illness Index,
pubmed-meshheading:18625622-Treatment Failure,
pubmed-meshheading:18625622-Treatment Outcome,
pubmed-meshheading:18625622-Tumor Necrosis Factor-alpha
|
|
pubmed:year |
2008
|
|
pubmed:articleTitle |
IL-6 receptor inhibition with tocilizumab improves treatment outcomes in patients with rheumatoid arthritis refractory to anti-tumour necrosis factor biologicals: results from a 24-week multicentre randomised placebo-controlled trial.
|
|
pubmed:affiliation |
Leeds Teaching Hospitals Trust, University of Leeds, Leeds, UK. p.emery@leeds.ac.uk
|
|
pubmed:publicationType |
Journal Article,
Randomized Controlled Trial,
Research Support, Non-U.S. Gov't,
Multicenter Study
|
